Description
The EORTC Breast Cancer Group (BCG) is a multidisciplinary group aiming to challenge, re-define and develop standards of care in all controversial areas of Breast Cancer diagnosis and therapy, including rare conditions such as male breast cancer. The group researches long-term outcomes and follows all patients until they die.
Related News
All newsRecruiting Clinical Trials
All clinical trials in this research field-
Phase 3
Management of low grade ductal carcinoma in situ (low-grade DCIS): a randomized, multicenter, non-inferiority trial, between standard therapy approach versus active surveillance
-
Cohort
Aiming to Understand the MOlecular Aberrations in Metastatic Breast Cancer
-
Cohort
Follow-up in Early and Locally Advanced Breast Cancer Patients: An EORTC QLG-BCG- ROG Protocol
-
Cohort
Improving Health-Related Quality of Life in Metastatic Breast Cancer. Taking stock of achievements and delivering better measurement
-
Phase 2
A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer (APPALACHES)
Main Achievements
Demonstrated breast-conserving therapy has similar efficacy compared to mastectomy (EORTC 10801)
Showed that chemotherapy before or after surgery yielded similar results in terms of survival (EORTC 10902)
Demonstrated that axillary radiotherapy after a positive sentinel lymph node provides excellent and comparable regional control when compared to axillary lymph node dissection, with the benefit of decreased morbidity (AMAROS)
Demonstrated that in some early-stage breast cancer, patients traditionally deemed high risk for disease recurrence based on clinical and biological criteria can have chemotherapy safely omitted without a difference in outcome, in case of a low-risk 70-gene signature result (MINDACT) More information
Related Projects
10085 (MALE BC)-related project
- RP 1539 (RNAseq): Male breast cancer RNA sequencing (Project leader: John Martens)
Status: Analyses of first 70 patients completed, additional analyses will follow. Plan is to submit an abstract with the first results for SABCS 2017.
10041 (MINDACT)-related projects
- RP 0906 (Blue Print): comparison of microarray readout with IHC/FISH for to molecular subtyping profile (BluePrint) (Project leaders: Fatima Cardoso, Giuseppe Viale, Femke de Snoo, Leila Russo, Lisette Stork-Sloots)
Status: Manuscript was submitted - RP 1556 (MINDACT multifocal): Characterisation of multifocal disease in the MINDACT study (Project leaders: Emiel Rutger, Anne Kuijer, Marieke Straver).
status: Manuscript was submitted
10994 (p53)-related projects
- RP 1644 (p53-LocoReg): Predictive factors of locoregional recurrence after neoadjuvant chemotherapy in locally advanced breast cancer: a retrospective analysis of the EORTC 10994/BIG1-02 study (Project leader: Hervé Bonnefoi)
Status: Manuscript was submitted
Research Group
Group documents-
Chair
Fatima Cardoso
Champalimaud Cancer Center
Lisbon, Portugal
-
Secretary
Etienne Brain
Institut Curie – Hopital Rene Huguenin
Paris, France
-
Treasurer
Emiel Rutgers
The Netherlands Cancer Institute
Antoni van LeeuwenhoekziekenhuisAmsterdam, Netherlands
Steering Committee
-
M. Arnedos - Villejuif, FR
/
Gustave Roussy
-
H. Bonnefoi - Bordeaux, FR
/
Institut Bergonie
-
D. Cameron - Edinburgh, GB
/
Western General Hospital
-
M. Ignatiadis - Brussels, BE
/
Institut Jules Bordet
-
B. Linderholm - Goteborg, SE
/
Sahlgrenska Universitetssjukhuet
-
K. Pogoda - Warsaw, PL
/
Maria Sklodowska-Curie Memorial Cancer Centre
-
A. Peric - Brussels, BE
/
EORTC Headquarters
-
C. Poncet - Brussels, BE
/
EORTC Headquarters
-
N. Russell - Amsterdam, NL
/
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis
-
E. Senkus-Konefka - Gdansk, PL
/
Medical University Of Gdansk
-
K. Tryfonidis - Brussels, BE
/
EORTC Headquarters
-
L. Van'T Veer - San Fransisco, US
/
UCSF Helen Diller Family Comprehensive Cancer Center
-
P. Vuylsteke - Namur, BE
/
CHU Ucl Namur - Site Sainte-Elisabeth
-
C. Drukker - Amsterdam, NL
/
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis
Notable Publications
All publications on this research field-
2020
Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials
-
2020
Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 5-year results of a randomised, phase 3 trial
-
2020
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial
-
2019
Reference Values for the EORTC QLQ-C30 in Early and Metastatic Breast Cancer
-
2019
Molecular apocrine-like tumors in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes